Drug Trial Radar · NCT04233437
Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Feb 10, 2020
Primary completion
May 16, 2020
Study completion May 16, 2020
Sponsor
- Lead sponsor
- Moleac Pte Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Moleac Australia Pty Ltd
- First posted
- Jan 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-centre phase I study to assess the Drug-Drug Interaction potential of MLC1501 with a cocktail of drugs acting as sensitive clinical probe substrates of Cytochrome P450 isoenzymes and Transporters in healthy subjects . The study will have 2 cohorts, one for the CYP study and the other for the Transporters study. Eligible subjects (n=24) will be assigned to one of the 2 cohorts in a 1:1 ratio.
Conditions
- Stroke
Interventions
MLC1501Drug
MLC1501 capsules (4 capcules (2000 mg) twice a day)
CYP CocktailDrug
Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg
Transporter CocktailDrug
Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in area under curve (AUC) of individual substrates is being assessed between cocktail alone and cocktail + MLC1501 administrationTime frame: Through study completion, an average of 29 days and 18 days for CYP and Transporter cohort, respectively.
- Change in maximum concentration (Cmax) of individual substrates is being assessed between cocktail alone and cocktail + MLC1501 administrationTime frame: Through study completion, an average of 29 days and 18 days for CYP and Transporter cohort, respectively.
- Change in time taken to reach maximum concentration (Tmax) of individual substrates is being assessed between cocktail alone and cocktail + MLC1501 administrationTime frame: Through study completion, an average of 29 days and 18 days for CYP and Transporter cohort, respectively.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.